Business Context and Reporting Period
Company: Bicycle Therapeutics plc
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2026
Business Overview: Bicycle Therapeutics is a clinical-stage pharmaceutical company developing Bicycle molecules, a novel class of medicines combining the pharmacology of biologics with the properties of small molecules. The company focuses on oncology indications. As of March 31, 2026, the company had no approved products and has not generated revenue from product sales.
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 2026 | Q1 2025 |
|---|---|---|
| Collaboration Revenue | $887 | $9,977 |
| Total Operating Expenses | $66,369 | $80,181 |
| Net Loss | $(60,825) | $(60,754) |
| Net Loss Per Share (Basic & Diluted) | $(0.87) | $(0.88) |
| Cash and Cash Equivalents (End of Period) | $559,474 | $792,973 |
| Net Cash Used in Operating Activities | $(65,925) | $(86,370) |
| Accumulated Deficit | $(960,576) | $(741,545) |
Material Changes vs. Prior Period
- Revenue Decline: Collaboration revenue decreased by $9.1 million (91%) compared to Q1 2025. This was primarily due to the termination of the Genentech collaboration (effective August 2025) and the Novartis collaboration (effective February 2026).
- Expense Reduction: Total operating expenses decreased by $13.8 million. Research and Development (R&D) expenses fell by $10.2 million, driven by reduced clinical program expenses for zelenectide pevedotin and lower share-based compensation. General and Administrative (G&A) expenses decreased by $3.7 million due to lower professional fees and share-based compensation.
- Workforce Reduction Charges: The company recognized $4.2 million in severance and termination benefits in Q1 2026 related to a strategic reprioritization and workforce reduction announced in March 2026 (approximately 30% of the workforce).
- Cash Position: Cash and cash equivalents decreased by approximately $68.6 million during the quarter, primarily due to operating cash outflows and foreign exchange impacts.
Guidance, Outlook, and Risks
- Strategic Reprioritization: In March 2026, the company announced a strategic shift to focus on next-generation therapeutics, specifically nuzefatide pevedotin (EphA2 BDC) and Bicycle Radioconjugates (BRC). The Phase II/III Duravelo-2 trial for zelenectide pevedotin is being converted to a randomized Phase II trial, and other trials for this candidate are being discontinued.
- Cost Savings: The workforce reduction and strategic reprioritization are expected to reduce annual operating expenses by approximately 50% based on current plans. Aggregate charges for the March 2026 reduction are expected to be approximately $7.2 million.
- Liquidity Outlook: Management expects cash and cash equivalents of $559.5 million to fund operations for at least 12 months from the filing date. The company anticipates needing additional funding in the future to support clinical development and commercialization.
- Risks: Key risks include the uncertainty of clinical trial outcomes, the need for additional capital, potential failure to achieve profitability, and reliance on third-party manufacturers and collaborators. The company also faces risks related to the new U.K. R&D tax credit regime and potential changes in global trade policies.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $559.5 million cash balance against the projected 50% reduction in operating expenses and the timeline for the next capital raise.
- Collaboration Revenue: Confirm the impact of the terminated Genentech and Novartis agreements on future revenue streams and the status of the remaining Bayer and Ionis collaborations.
- Workforce Reduction Execution: Monitor the completion of the 30% workforce reduction and the realization of the projected $7.2 million in aggregate charges and long-term cost savings.
- Clinical Pipeline Status: Review the progress of the nuzefatide pevedotin Phase II trial in pancreatic ductal adenocarcinoma and the conversion of the zelenectide pevedotin Duravelo-2 trial.
- U.K. Tax Credits: Assess the company's continued qualification as "R&D intensive" under the U.K. Finance Act 2024 to ensure the continuation of the 26.97% cash rebate on qualifying R&D expenditure.